SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as discussions shift towards its AI capabilities and potential market dominance, with some believing it could surpass competitors like NVDA. Community members are analyzing its valuation, debating whether it's overbought, and anticipating further upside. The spotlight is on GOOG's AI advancements and its strategic positioning within the tech landscape.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around the idea of turning "broke" into an advantage amid market uncertainty, emphasizing resilience and long-term building. Discussions focus on community strength, accumulating during dips, and potential for a significant reversal. The community highlights ongoing development and revenue-generating utilities, aiming for a comeback and a "moon" mission.

shark raptor rocket launcher

SRRL is gaining attention, with community members pointing to its strong chart and steady volume as potential bullish signals. Conversations mention the formation of a "clean range," and some express excitement about a potential breakout. Others urge caution, suspecting pump and dump activity.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zoom Video Communications, Inc.

Zoom ($ZM) is trending as traders discuss its Q3 earnings beat and raised guidance, including an additional $1B buyback authorization. Community members are debating the stock's valuation, cash flow, and the impact of AI on its future growth, as well as insiders dumping shares.  Some see it as undervalued and poised for a rally towards $90-$100, while others express skepticism due to competition and limited growth.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAL is trending amid discussions about a recent equity distribution agreement and its potential impact on share dilution, with community members weighing the significance of capital raising efforts. Bullish sentiment remains due to the company's game-changing technology and potential for long-term growth in cancer screening, while others express concerns about valuation and competition. Options traders are actively trading calls and puts, reflecting differing perspectives on GRAL's short-term trajectory.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors weigh its AI prospects against competitors, particularly after the release of Gemini 3 and news of Meta potentially using Google's TPUs. Community discussions revolve around whether GOOGL can challenge Nvidia's dominance and the stock's valuation amid broader AI hype, with some suggesting it's undervalued while others foresee a correction.

Kaspa was fair-launched in November 2021 with no pre-mine, zero pre-sale, and no coin allocations, and is 100 percent community-managed. Kaspa aims to be the world's global sequencer for traditional finance and decentralized crypto markets by utilizing proof-of-work and its BlockDAG consensus protocol, GHOSTDAG. Being the world's fastest proof-of-work network, Kaspa combines five properties: (1) hard money principles, (2) Bitcoin's ethos of security-first fundamentals (boasting a security threshold of fifty percent with significant market hashrate), (3) decentralization from rapid block rate mining, (4) block speeds faster than any PoW or PoS network, and (5) smart contract development through based-rollups without fragmented liquidity. Ushering in all five properties, Kaspa is on track to fulfill Satoshi Nakamoto's vision of a digital medium of exchange while also advancing global layer-one sequencing and minuscule confirmation times dominated by internet latency (cf. chapter 6 of the the paper for some initial benchmarks). The Kaspa implementation includes a lot of cool features and subprotocols including Reachability to query the DAG's topology, Block data pruning (with near-future plans for block header pruning), SPV proofs, and later subnetwork support which will make future implementation of layer 2 solutions much easier.

Kaspa

Kaspa is trending as the community discusses its potential for future growth, spurred by the approaching launch of smart contracts. Positive sentiment is building about Kaspa's technology and potential listings on major exchanges, although some traders remain skeptical, citing past performance. Discussions also include real-world assets.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America and Australia (NAA) Cruise, Europe and Asia (EA) Cruise Operations, Cruise Support, and Tour and Others. The North America and Australia (NAA) Cruise segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe and Asia (EA) Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

CCL is trending due to a sudden drop in cruise line stocks, with community members debating the cause, ranging from concerns about a cautious outlook on the U.S. macroeconomy and capacity growth in the Caribbean to potential manipulation and even geopolitical tensions with Venezuela. Some traders are looking to buy the dip, while others express concerns about the sector's volatility and debt levels. The cruise line sector is down overall, sparking discussions about fair value and market manipulation.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is trending due to discussions around technical analysis, potential overbought conditions, and analyst ratings adjustments for key holdings like NVDA and AMD. Community members are actively debating whether the ETF is setting up for a correction or has more room to run, while also weighing the impact of potential geopolitical factors and earnings reports.

Aave is a decentralized money market protocol where users can lend and borrow cryptocurrency across 20 different assets as collateral. The protocol has a native token called AAVE, which is also a governance token that lets the community decide the direction of the protocol in a collective manner. Lenders can earn interest by providing liquidity to the market, while borrowers can borrow by collateralizing their cryptoassets to take out loans from the liquidity pools.

AAVE

Aave is trending as community members discuss its potential for growth and recent whale activity, with some suggesting it's undervalued compared to competitors like Compound. The launch of Aave's savings app and integration with traditional finance platforms like Robinhood are also sparking interest. Traders are watching Aave as a leading DeFi protocol, anticipating potential gains amidst regulatory clarity and protocol upgrades.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2025 EPS Estimate for Palisade Bio Increased by Analyst

Palisade Bio, Inc. (NASDAQ:PALI - Free Report) - Analysts at Brookline Capital Management upped their FY2025 earnings per share estimates for shares of Palisade Bio in a research note issued to...

Palisade Bio (NASDAQ:PALI) Announces Earnings Results, Misses Estimates By $0.06 EPS

Palisade Bio (NASDAQ:PALI - Get Free Report) issued its earnings results on Monday. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.32) by...

Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Palisade Bio (PALI), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

All You Need to Know About Palisade Bio (PALI) Rating Upgrade to Buy

Palisade Bio (PALI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Retail traders piled into Palisade Bio on Wednesday after the biotech company said it would raise approximately $120 million from an underwritten public offering.The stock soared 52.4% on Wednesday to close at $0.45, marking its best session in more than nine months, and gained another 9.5% in after-hours trading.Palisade will offer approximately 171.4 million shares of its common stock, or its equivalent, at $0.70 per share. The underwriters also have an option to purchase about 25.7 million shares at $0.70 for a period of 45 days. Ladenburg Thalmann &amp; Co. Inc. is leading the process, which is expected to close on October 2.The company further stated that the proceeds from the deal will be used to fund its drug pipeline, targeting autoimmune, inflammatory, and fibrotic conditions.The fresh fundraising follows a series of recent developments on the drug development front. Last month, Palisade reported positive early-stage data from its experimental drug PALI-2108 in the treatment of inflammatory bowel diseases. In a small ulcerative colitis trial, the treatment was found to improve outcomes for all patients, with two patients achieving complete remission. The drug was also found to be safe and well-tolerated in a prior study.Palisade also recently secured regulatory approval in Canada to commence an early-stage trial of PALI-2108 in fibrostenotic Crohn’s disease. The study is expected to kick off later this year and will deliver its first data in early 2026.On Stocktwits, retail sentiment for Palisade Bio was ‘extremely bullish’ amid a 33,300% surge in 24-hour message volume.One user stated that the stock appeared strong in overnight trading and expected it to reach $2 by Thursday. At the same time, another predicted that Palisade Bio could rally further next week following weekend data updates.<stembedurl>https://stocktwits.com/Tazdoc88/message/630728209</stembedurl><stembedurl>https://stocktwits.com/smolcapcat/message/630723724</stembedurl><a href="https://stocktwits.com/symbol/PALI">Palisade Bio’s stock</a> has declined 20.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Palisade Bio’s stock (PALI) has declined 20.6% so far in 2025. (Photo credit: Getty Images)

Palisade Bio Stock Climbs To 9-Month High After $120M Stock Offering; Retail Sees More Gains Ahead

The rally came as traders reacted to its $120 million capital raise, aimed at accelerating development of new therapies for autoimmune, inflammatory, and fibrotic diseases.

Equity

Palisade Bio Announces 1-for-15 Reverse Stock Split

Carlsbad,CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), ( Palisade , Palisade Bio or the Company ), a biopharmaceutical company focused on developing and...

Palisade Bio files to sell 3.63M shares of common stock for holders

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Analysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)

Theres a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inventiva (IVA Research Report) and Palisade Bio...

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end Formation of Clinical...

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

Carlsbad,CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ( Palisade or the Company ), a biopharmaceutical company focused on developing novel therapeutics for...

This account has been verified as an official PALI representative.

Verified Account

Palisade Bio

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.

Palisade Bio Inc

Buying

Holding

Selling or trimming

Watching from the sidelines

What are you doing with Alphabet ($GOOGL) stock as it hits fresh all-time highs?

Current Price	$2.28
Prev Close	$2.13
Open	$2.15
Dividend Yield	0.00%
50-Day Moving Average	$1.62
Beta	1.19
Avg. Volume	17.5M
PE Ratio	-0.54

52-Week High	$3.30
52-Week Low	$0.53
Market Capitalization	$317.38M
EPS (Annual)	-$10.19
Price to Book	6.48
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PALI
Palisade Bio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest PALI News

PALIPalisade Bio Inc